9.23
-0.04(-0.43%)
Currency In USD
| Previous Close | 9.27 |
| Open | 9.5 |
| Day High | 9.5 |
| Day Low | 9.03 |
| 52-Week High | 54.95 |
| 52-Week Low | 5.01 |
| Volume | 2,499 |
| Average Volume | 295,668 |
| Market Cap | 5.43M |
| PE | -0.27 |
| EPS | -34.62 |
| Moving Average 50 Days | 7.83 |
| Moving Average 200 Days | 15.05 |
| Change | -0.04 |
If you invested $1000 in Quoin Pharmaceuticals, Ltd. (QNRX) since IPO date, it would be worth $0.58 as of July 01, 2025 at a share price of $9.23. Whereas If you bought $1000 worth of Quoin Pharmaceuticals, Ltd. (QNRX) shares 5 years ago, it would be worth $4.96 as of July 01, 2025 at a share price of $9.23.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases
GlobeNewswire Inc.
Jun 26, 2025 12:30 PM GMT
New episode spotlights the severe burden of Netherton Syndrome in infants and children, reinforcing the need for effective pediatric treatmentsASHBURN, Va., June 26, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
GlobeNewswire Inc.
Jun 24, 2025 12:30 PM GMT
ASHBURN, Va., June 24, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and
Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study
GlobeNewswire Inc.
May 22, 2025 11:30 AM GMT
Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects.Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. Amy Paller a